Gilead’s herpes candidate cut viral shedding by 98%. What will its latest IDWeek data reveal?
Gilead will present 28 studies at IDWeek 2026, covering Bixlenvo treatment outcomes, early real-world Yeztugo adoption and final Phase 1b findings for the investigational herpes medicine GS-1179. The programme examines how recently approved HIV treatments perform in practice while advancing a separate long-acting antiviral candidate.
